Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Interleukin-8 inhibition by reparixin protects megakaryocytes and alleviates thrombocytopenia in Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JHJing-Li HanJZJianying ZhouTWTing Wang

Discussion

Loading...

Member takes

Overview

Experimental findings reveal reparixin preserves megakaryocyte function and platelet levels in AML, suggesting new treatment avenues.

Key Points

  • To evaluate the impact of interleukin-8 on megakaryocyte biology and the potential of reparixin in alleviating thrombocytopenia associated with AML.
  • Utilized two mouse models: IL-8 treated wild-type C57BL/6 mice and AML-inducing THP-1 cells in SCID mice.
  • Monitored hematological parameters, including tail-bleeding time and flow cytometric analysis of bone marrow cells.
  • Administered reparixin alongside azacitidine and venetoclax in one model to assess platelet recovery.
  • IL-8 treatment significantly reduced CD41+ megakaryocytes and platelet counts, prolonging bleeding time.
  • Reparixin treatment restored megakaryocyte progenitors and platelet counts during hematologic recovery after chemotherapy.
  • Findings indicate interleukin-8 hinders megakaryopoiesis, mirroring outcomes in acute myeloid leukemia.

Cite This Study

Han et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4a7https://doi.org/10.1182/blood-2025-3235
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Paquinimod regulate megakaryocyte function by restoring mitochondrial oxidative phosphorylation in acute myeloid leukemia2025
  2. 2Single-cell transcriptomic studies reveal altered heterogeneity in CD41 enriched megakaryocytes after targeted therapy in myeloproliferative neoplasm2025
  3. 3FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML2023 · 19 citations
  4. 4EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)2025 · 2 citations
  5. 5Selective targeting of RSK signaling with PMD-026 suppresses FLT3-activated acute myeloid leukemia while sparing normal hematopoiesis2026 · 1 citations